Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm2(tetO-Pou5f1)Jae}
• Allele Name: targeted mutation 2, Rudolf Jaenisch
• Allele ID: MGI:3702325
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Col1a1^tm2(tetO-Pou5f1)Jae/Col1a1^+ Gt(ROSA)26Sor^tm1(tTA)Roos/Gt(ROSA)26Sor^+ Lgr5^tm1(cre/ERT2)Cle/Lgr5^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J	MGI:5508640
cx2	Col1a1^tm2(tetO-Pou5f1)Jae/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6	MGI:3703249

Genotype
MGI:5508640

cn1

• Allelic Composition: Col1a1^{tm2(tetO-Pou5f1)Jae}/Col1a1⁺; Gt(ROSA)26Sor^tm1(tTA)Roos/Gt(ROSA)26Sor⁺; Lgr5^{tm1(cre/ERT2)Cle}/Lgr5⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

digestive/alimentary system

abnormal small intestine crypts of Lieberkuhn morphology ( J:199754 )

• expanded crypts in the ileum of doxycycline-treated mice

abnormal intestine physiology ( J:199754 )

• increased cell proliferation in the intestine of doxycycline-treated mice without an increase in Lgr5+ cells

cellular

increased cell proliferation ( J:199754 )

• in the intestine of doxycycline-treated mice without an increase in Lgr5+ cells

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:199754 )

• expanded crypts in the ileum of doxycycline-treated mice

Genotype
MGI:3703249

cx2

• Allelic Composition: Col1a1^{tm2(tetO-Pou5f1)Jae}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:98920 )

• mice with doxycycline-induced ectopic Oct4 expression become morbid after 3-5 days of treatment and usually die after 5-10 days of treatment

• however, if doxycycline treatment is stopped after 5 days mice completely recover

digestive/alimentary system

abnormal intestinal epithelium morphology ( J:98920 )

• after doxycline treatment, dysplastic cells are found in the entire epithelium; cells have structural and cytological dysplasia which mimics adenocarcinoma

abnormal small intestine morphology ( J:98920 )

• the proximal part of the small intestine is most severely affected by doxycycline treatment with abnormal cells often almost obstructing the lumen

• after 5 days of doxycycline treatment, proliferative zone expands; postmitotic, differentiated cells lining the villus are replaced

• upon cessation of treatment, cells migrate to final destinations and differentiate resulting in restoration of normal morphology

abnormal forestomach morphology ( J:98920 )

• in doxycycline treated mice, cells in the forestomach show a marked atypia and increased mitotic activity

abnormal stomach mucosa morphology ( J:98920 )

• pyloric mucosa contains lesions resembling high grade-dysplasia in doxycycline treated mice

abnormal intermediate gastric gland morphology ( J:98920 )

• hyperplastic fundic glands are seen in doxycycline treated mice

abnormal stomach epithelium morphology ( J:98920 )

• in doxycycline treated mice, forestomach epithelium is thickened and stomach shows lack of differentiation into granular and cornified cell layers compared to control mice

• the thickened epithelium consists of atypical cells with enlarged nuclei and prominent nucleoli

abnormal stomach glandular epithelium morphology ( J:98920 )

• after doxycycline treatment, mice display severe dysplasia and increased proliferation

stomach epithelial hyperplasia ( J:98920 )

• cells show atypia and increased mitotic activity throughout the squamous epithelial layer in doxycycline treated mice

homeostasis/metabolism

dehydration ( J:98920 )

• after 3-5 days of doxycycline treatment, animals display severe dehydration

cellular

abnormal cell proliferation ( J:98920 )

• abnormal cell proliferation is observed in several organs after 2 days of Oct4-induction

• however, complete reversion is seen with withdrawal of doxycycline treatment

behavior/neurological

lethargy ( J:98920 )

• animals become lethargic with doxycycline treatment within 3-5 days

hematopoietic system

thymus atrophy ( J:98920 )

• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice

spleen atrophy ( J:98920 )

• in doxycycline treated mice

immune system

thymus atrophy ( J:98920 )

• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice

spleen atrophy ( J:98920 )

• in doxycycline treated mice

neoplasm

increased skin tumor incidence ( J:98920 )

• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen

integument

abnormal hair follicle morphology ( J:98920 )

• increased numbers of immature cells in the hair follicles of the skin are seen after 5-10 days of doxycycline

abnormal epidermal layer morphology ( J:98920 )

• after 5-10 days of doxycycline treatment, mice show mild to moderate epidermal dysplasia with a decrease in differentiation in dysplastic cells

increased skin tumor incidence ( J:98920 )

• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen

endocrine/exocrine glands

abnormal intermediate gastric gland morphology ( J:98920 )

• hyperplastic fundic glands are seen in doxycycline treated mice

thymus atrophy ( J:98920 )

• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice